黑料网

Since the beginning of the SARS-CoV-2 outbreak, antiphospholipid antibodies (aPL), a known thrombotic risk factor, have been studied in COVID-19 patients, in whom thromboembolic events have been associated with poor prognosis [1]. The association between infections and aPL is historically known, causing transient positivity for aPL or representing the so-called “second hit” in causing thrombosis in APS patients [2]. The prevalence of aPL in COVID-19 patients is variable, ranging from 8.3% to 74% [3-6]. Furthermore, these studies are heterogeneous and difficult to compare: in some studies, aPL has been searched in critical COVID-19 patients, a condition associated with a greater thrombotic risk [5], in others aPL has been tested in patients with varying degrees of COVID-19 severity [7]. In addition, aPL levels are not reported in all studies and LA was sometimes performed in patients on anticoagulant therapy, with the risk of false positivity [8,9]. To date, the pathogenetic role of aPL and the antibodies trend over time are still unknown. Aim of the present study was to investigate whether aPL positivity correlated with thrombosis in COVID-19 patients and whether it was transient or persistent.

Patients

We included all consecutive COVID-19 patients hospitalized in one of the COVID-19 Units of the Policlinico Umberto I, Sapienza University of Rome from April 1, 2020 to June 7, 2020 in this prospective study. The diagnosis of SARS-CoV-2 infection was confirmed in all the patients by nasopharyngeal swab for SARS-CoV-2 on real- time Reverse-Transcriptase–Polymerase-Chain-Reaction (RT-PCR). Patients ‘exclusion criteria were: Non-COVID-19 patients and patients affected by Autoimmune Inflammatory Rheumatic Diseases (AIIRD). This study was approved by the local ethic committees and participants gave written informed consent.

Methods

IgG and IgM aCL and aβ2-GPI were detected by chemiluminescence assay using Zenit RA Immunoanalyzer (A. Menarini Diagnostics, Florence, Italy), IgA aCL by EliA detection kit by ThermoFisher Scientific (Waltham, USA). LA was analyzed using two coagulation systems, a dilute sensitized activated partial thromboplastin time (aPTT) and a Dilute Russell’s Viper Venom Time (dRVVT), and then performing a confirmatory test with reagents and instrumentation by Hemoliance Instrumentation Laboratory, Lexington, MA, USA.

Statistical analysis

Data are expressed as mean ± Standard Deviation (S.D.) or median (interquartile range) according to the distribution of the variables. χ²-test or Fisher exact test was used for comparison of categorical variables. P values<0.05 were considered statistically significant. SPSS 20.0 statistical software package (SPSS Inc., Chicago, IL, USA) was utilized for all statistical tests.

We enrolled 73 hospitalized patients affected by COVID-19 (40 females and 33 males, all Caucasian) with a mean age of 65 years (SD. 17.6). Clinical and demographic characteristics of COVID-19 are reported in (Table 1). The most common symptoms at disease onset were fever (82%), dyspnea (60%) and cough (31.5%); the median time from appearance of the first symptoms to hospital admission and positive nasopharyngeal swab for SARS-CoV-2 on RT-PCR assay was 5 days (IQR 9.25). In 64 out of 73 patients (87.7%) bilateral distribution of patchy shadows or ground-glass opacity were found in High Resolution Computed Tomography (HRCT) of the chest, the remaining patients did not show any sign of pneumonia. Almost all patients (75%) reported at least one comorbidity; in addition, 8 (10.9%) patients presented a medical history of arterial thrombosis and one (1.4%) patient reported a history of venous thrombosis.

Table 1: Clinical and demographic features of the 73 Covid-19 patients.

Twenty eight out of 73 (38.4%) patients were found positive for at least one aPL assay at low-medium titer. Twenty-four out of 73 (32.8%) patients showed positivity for IgA aCL, 5/73 (6.8%) for IgM aCL and 3/73 (4.1%) for IgM aβ2GPI. Among the positive patients 24 out 28 (85.7%) patients showed positivity for IgA aCL, 5/28 (17.8%) were found positive for IgM aCL and 3/28 (10.7%) for IgM aβ2GPI. IgG aCl and IgG aβ2GPI were negative in all patients. At the time of hospitalization, LA test was performed only in 12 patients who were not on anticoagulant therapy, no patients tested positive.

Seven out 73 (9.6%) patients developed thrombotic events during hospitalization, among them 4 (57%) tested positive for aPL (Table 2).

Table 2: Clinical and demographic features of the 7 Covid-19 patients that developed thrombotic events.

We observed that the risk of death was 9-fold higher in patients with thrombotic events during hospitalization (likelihood positive ratio (LR+) 8.9, p=0.003) and that patients with double positivity for IgM aCL and IgM aβ2GPI had a LR+ of 6.3 to have thrombotic events (p=0.012) and a LR+ of 4.9 to have an increase in D-dimer levels (p=0.027). IgA aCL, the most prevalent aPL, did not result associated with thrombosis.

At follow-up, 10 out of the 28 aPL positive patients died, 8/28 were lost to follow-up. Ten aPL positive patients, 3 men and 7 women (mean age of 55.9 years (S.D. 20.8)), were tested for aPL on a second occasion at least 12 weeks apart from the first determination. None of them had a previous medical history of thrombosis, one patient reported an obstetrical history of 2 fetal deaths.

Overall, only 2/10 (20%) patients confirmed the positivity for at least one aPL assay. These patients tested positive for LA while at the first determination were positive for IgA aCL; at baseline LA test was not performed as they were on anticoagulant therapy. Both 2 patients had no previous or recent history of arterial and/or venous thrombosis, pregnancy morbidities or extra-criteria manifestations suggestive of APS.

Among the 4 patients who developed at least one thromboembolic event during hospitalization and who tested positive for aPL at the first determination, it was possible to repeat the aPL tests after 12 weeks only in one patient (a 74 years-old female) who had experienced three thrombotic events (myocardial infarction, peripheral arterial thrombosis, peripheral venous thrombosis) and she was found negative. The other 3 patients died during hospitalization due to complications of SARS-CoV-2 infection.

The results of the present study confirm that thrombotic events increase the risk of death in COVID-19 patients. In addition, we showed that, in COVID-19 patients, double positivity for IgM aCL and IgM aβ2GPI could increase the risk of thrombotic events. For the first time, in this study, we evaluated the persistence of aPL after 12 weeks since the first determination.

It’s well known that infections may lead to transient aPL positivity without clinical manifestations or trigger aPL-related features. To explain such phenomena various possible mechanisms have been proposed, such as molecular mimicry, post-translational modifications, exposition of self-antigens on the cell surface [10]. A wide variety of infectious agents have been linked to aPL positivity, such as CMV, EBV, HIV, HBV, HCV and parvovirus B19 [11,12]. In a systematic review, aPL have been detected in 293 patients during 50 different infections.

Among these patients, 72 patients fulfilled APS criteria, 128 patients reported a thrombotic event in association with a transient aPL positivity and 93 patients did not show any association between aPL and APS-related features [13].

In patients with SARS-CoV-2 infection, aPL has been detected in a variable range of subjects (8.3%-74%) [3-6]. In our study, 38.4% of COVID-19 patients showed positivity for at least one aPL assay at low-medium titer. In agreement with a previous Chinese study, the IgA isotype was found to be the most prevalent aPL in our cohort; those authors suggested that SARS-CoV-2 may preferentially induce the IgA isotype of aPL due to SARS-CoV-2 mucosal tropism. [4]. In our study IgA aCL wasn’t associated with thrombotic events, therefore IgA aCL could be an epiphenomenon.

The possible pathogenetic role of aPL in COVID-19 is still far from being clear; we observed that COVID-19 patients with double positivity for IgM aCL and IgM aβ2GPI have a 6-fold increased risk of thrombotic events and a 5-fold increased risk of higher D-dimer plasma levels. Besides, thrombotic events appeared to increase the risk of death (LR ± 8.9, p=0.003).

Xiao and colleagues evaluated the dynamic changes in aPL levels in 6 COVID-19 patients over a period of 60 to 77 days from disease onset; the results obtained suggest that aPL levels are fluctuating and they encouraged further studies with a long-term follow-up on COVID-19 patients positive for aPL [4]. Indeed, to date, only 2 case reports have tested aPL on a second occasion after at least three months in aPL positive COVID-19 patients [14,15].

At the best of our knowledge, this is the first study in which aPL- positive COVID-19 patients were re-tested after at least 12 weeks apart. The results of our study suggest that the 20% of COVID-19 patients may show persistent positivity for aPL. Given that aPL is a thrombotic risk factor, it may be appropriate to monitor antibodies trend over time and minimize other thrombotic risk factors in patients with SARS- CoV-2 infection.

The main limitations of our study are represented by the small sample size and the one-center design. Our results should be validated in larger and multicenter studies.

In conclusion, the results of our study confirm that thrombotic events increase the risk of death in COVID-19 patients and suggest that double positivity for aCL and aβ2GPI IgM could increase the risk of thrombosis in patients, unlike positivity for IgA aCL.

Antiphospholipid antibodies positivity resulted to be persistent in a small percentage of COVID-19 patients, given that aPL is a thrombotic risk factor, it may be appropriate to monitor antibodies trend over time and minimize other thrombotic risk factors in patients with SARS- CoV-2 infection.

No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.

None declared.

1. Zhou F, Yu T, Du R, Fan G, Liu Y, et al. (2020) . Lancet 28:1054-1062.

   [] [] []

2. Uthman IW, Gharavi AE (2002) . Semin Arthritis Rheum 31:256-63.

   [] [] []

3. Galeano-Valle F, Oblitas CM, Ferreiro-Mazón MM, Alonso-Muñoz J, Del Toro-Cervera J, et al. (2020) . Thromb Res 192:113-5.

   [] [] []

4. Xiao M, Zhang Y, Zhang S, Qin X, Xia P, et al. (2020) . Arthritis Rheumatol 72:1998-2004.

   [] [] []

5. Pineton de Chambrun M, Frere C, Miyara M, Amoura Z, Martin-Toutain I, et al. (2021) . J Intern Med 289:422-4.

   [] [] []

6. Devreese KMJ, Linskens EA, Benoit D, Peperstraete H (2020) . J Thromb Haemost 18:2191-201.

   [] [] []

7. Borghi MO, Beltagy A, Garrafa E, Curreli D, Cecchini G, et al. (2020) . Front Immunol 11:584241.

   [] [] []

8. Bowles L, Platton S, Yartey N, Dave M, Lee K, et al.  (2020) . N Engl J Med 383:288-90.

   [] [] []

9. Harzallah I, Debliquis A, Drénou B (2020) . J Thromb Haemost 18:2064-5.

   [] [] []

10. Radic M, Pattanaik D (2018) . Front Immunol 9:969.

    [] [] []

11. Cervera R, Asherson RA (2005) . Immunobiology 210:735-41.

    [] [] []

12. Sene D, Piette JC, Cacoub P (2009) . Rev Med Interne 30:135-41.

    [] [] []

13. Abdel-Wahab N, Lopez-Olivo MA, Pinto-Patarroyo GP, Suarez-Almazor ME (2016) . Lupus 25:1520-31.

    [] [] []

14. Loos CMJ, Yperzeele L, Jadoul C, Baar I, Jorens PG (2021) . Acta Neurologica Belgica 2:1-3.

    [] [] []

15. Balanchivadze N, Xie P, Kuriakose P, Barthel B, Dabak V (2021) . Cureus 13:e13026.

    [] [] []